Stevenage, United Kingdom

Christopher James Lunniss

USPTO Granted Patents = 10 

 

Average Co-Inventor Count = 5.1

ph-index = 3

Forward Citations = 53(Granted Patents)


Company Filing History:


Years Active: 2007-2014

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovative Journey of Christopher James Lunniss

Introduction

Christopher James Lunniss, an accomplished inventor based in Stevenage, GB, has made significant contributions to the field of pharmaceutical research. With a total of 10 patents to his name, Lunniss has been pivotal in developing novel compounds aimed at targeting specific biological activities, particularly in the realm of PI3-kinase inhibition.

Latest Patents

Among Lunniss's latest innovations are two noteworthy patents focusing on inhibitors of PI3-kinase activity. The first patent is directed to compounds of a specified formula and their salts, emphasizing their effectiveness as PI3-kinase inhibitors. The second invention, titled "Benzpyrazol Derivatives as Inhibitors of PI3 Kinases," also presents novel compounds designed to combat PI3-kinase activity, reinforcing Lunniss's expertise in pharmaceutical innovation.

Career Highlights

Throughout his professional journey, Lunniss has been associated with prominent organizations, including Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited. His work at these companies has allowed him to harness his inventiveness and contribute to significant advancements in drug development and intellectual property.

Collaborations

Lunniss has collaborated with remarkable colleagues, including Alison Judith Redgrave and Julie Nicole Hamblin. These partnerships have undoubtedly enriched his professional experience and have fostered an environment conducive to innovation.

Conclusion

Christopher James Lunniss exemplifies the innovative spirit necessary in the field of pharmaceutical sciences. His work on PI3-kinase inhibitors indicates a deep understanding of biochemical pathways and the impact of targeted therapies. As he continues to expand his portfolio of patents, the contributions of Lunniss will surely play a critical role in the future of medical research and patent development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…